AR040420A1 - INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - Google Patents

INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Info

Publication number
AR040420A1
AR040420A1 ARP030102429A AR040420A1 AR 040420 A1 AR040420 A1 AR 040420A1 AR P030102429 A ARP030102429 A AR P030102429A AR 040420 A1 AR040420 A1 AR 040420A1
Authority
AR
Argentina
Prior art keywords
treatment
bacterial infections
prevention
pulmonary bacterial
pseudomonas aeruginosa
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Alan Bruce Montgomery
Original Assignee
Salus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salus Pharma Inc filed Critical Salus Pharma Inc
Priority to ARP030102429 priority Critical patent/AR040420A1/en
Publication of AR040420A1 publication Critical patent/AR040420A1/en

Links

Abstract

Un método y una composición para el tratamiento de las infecciones bacterianas pulmonares provocadas por bacterias gram-negativas adecuados para el tratamiento de infecciones provocadas por, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, especies de Enterobacter, Serratia marcescens, y también aquéllas provocadas por Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans y Pseudomonas aeruginosa resistente a múltiples drogas utilizando una formulación concentrada de aztreonam o una sal farmacéuticamente aceptable del mismo, liberadas como una formulación en aerosol o en polvo seco.A method and composition for the treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for the treatment of infections caused by, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens, and also those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and Pseudomonas aeruginosa resistant to multiple drugs using a concentrated formulation of aztreonam or a pharmaceutically acceptable salt thereof, released as an aerosol or dry powder formulation.

ARP030102429 2003-07-04 2003-07-04 INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS AR040420A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP030102429 AR040420A1 (en) 2003-07-04 2003-07-04 INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP030102429 AR040420A1 (en) 2003-07-04 2003-07-04 INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
AR040420A1 true AR040420A1 (en) 2005-04-06

Family

ID=42777433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102429 AR040420A1 (en) 2003-07-04 2003-07-04 INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Country Status (1)

Country Link
AR (1) AR040420A1 (en)

Similar Documents

Publication Publication Date Title
BR0116757A (en) Method for treating pulmonary infections caused by gram-negative bacteria and pharmaceutically acceptable inhalation composition.
CY1114621T1 (en) INSPECTION OF INHIBITED LYSINIC AZRTEONAMINE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
WO2011005354A3 (en) Gallium formulation for the treatment and prevention of infectious diseases
JP2017510580A5 (en)
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
KR20170008762A (en) I- gold iphosphine compounds as antibacterial agents
CL2008001469A1 (en) Use of compounds derived from 3,5-bithenyl-1,2,4-triazole for the treatment of p.aeruginosa biofilm formation in a patient with cystic fibrosis; and a pharmaceutical combination comprising a compound of formula I and an antibiotic selected from gentamicin, amikacin, tobramycin, ciprofloxacin, among others.
JP2018500387A5 (en)
KR20170012288A (en) I- gold iphosphine compounds as antibacterial agents
Cote et al. Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents
AU2023285900A1 (en) Method For Reducing Lung Infection
AR040420A1 (en) INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Lin et al. Cyclic Diguanylate G-Quadruplex Inducer-Nitric Oxide Donor Conjugate as a Bifunctional Antibiofilm Agent and Antibacterial Synergist against Pseudomonas aeruginosa with a Hyperbiofilm Phenotype
AR054219A1 (en) FORMULATION OF INHALABLE AZTREONAM LISINATE FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS
CY1114144T1 (en) INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Kumar et al. Ertapenem for multiple β-lactamases producing Gram-negative bacteria causing urinary tract infections in HIV patients
Sumithra et al. Efflux pump inhibitors for antibacterial therapy.
Chirra et al. Antimicrobial Efficacy and Targeted Nanoparticle Delivery of Silver Ibuprofen to Treat Multi-Drug Resistant Gram-Positive and Gram-Negative Pathogens
Scheeren et al. Clinical cure and mortality outcomes with ceftobiprole medocaril versus ceftazidime plus linezolid in patients with early versus late-onset hospital-acquired pneumonia.

Legal Events

Date Code Title Description
FC Refusal